Table 2.
Cumulative Incidences of 3-Year Relapse and Non-Relapse Mortality (NRM)
| Relapse 3 yr | NRM 3 yr | ||||
|---|---|---|---|---|---|
| Covariates | N | Probability(95% CI) | p | Probability(95% CI) | p |
| Age in decades | 0.08 | 0.07 | |||
| 55-60 | 123 | 47 (38-56)% | 23 (15-31)% | ||
| 61-65 | 105 | 53 (43-62)% | 22 (14-30)% | ||
| 66+ | 45 | 33 (20-48)% | 40 (26-56)%ǂ | ||
| Karnofsky score | 0.30 | 0.006 | |||
| <=80 | 101 | 43 (33-53)% | 34 (25-43)% | ||
| 90-100 | 153 | 50 (42-58)% | 18 (12-24)% | ||
| Disease status | 0.13 | 0.72 | |||
| CR1 | 195 | 43 (36-50)% | 24 (18-30)% | ||
| >=CR2 | 47 | 57 (43-71)%ǂ | 28 (16-41)%ǂ | ||
| PIF/Rel | 29 | 56 (37-73)%ǂ | 30 (14-48)%ǂ | ||
| Conditioning regimen | 0.90 | 0.44 | |||
| Low-dose TBI based | 92 | 45 (35-55)% | 28 (19-37)% | ||
| Alkylating agent based | 170 | 48 (40-56)% | 23 (17-30)% | ||
| Other | 11 | 50 (21-79)%ǂ | 40 (13-70)%ǂ | ||
| Type of donor | 0.65 | 0.44 | |||
| Matched sib | 92 | 49 (39-60)% | 20 (12-29)% | ||
| MUD | 104 | 44 (34-53)% | 26 (18-35)% | ||
| UCB | 21 | 57 (36-77)%ǂ | 25 (9-46)%ǂ | ||
| Other& | 56 | 45 (32-58)%ǂ | 33 (21-46)%ǂ | ||
| GVHD prophylaxis | 0.81 | 0.48 | |||
| CsA/tacrolimus + MTX | 104 | 48 (38-58)% | 21 (13-29)% | ||
| CsA/tacrolimus + MMF | 117 | 45 (36-54)% | 28 (20-36)% | ||
| Other | 49 | 51 (36-65)%ǂ | 25 (14-39)%ǂ | ||
| In-vivo T-cell depletion | 0.004 | 0.73 | |||
| No | 189 | 41 (34-48)% | 26 (20-32)% | ||
| Yes | 83 | 60 (49-70)%ǂ | 24 (15-34)% | ||
| Year of HCT | 0.41 | 0.99 | |||
| 2000-2006 | 73 | 51 (39-63)% | 25 (16-36)% | ||
| 2007-2012 | 200 | 45 (38-53)% | 25 (19-32)% | ||
| Prior fungal infections* | 0.21 | 0.004 | |||
| No | 107 | 54 (44-63)% | 20 (13-28)% | ||
| Yes | 10 | 33 (8-65)%ǂ | 67 (35-92)%ǂ | ||
| Cytogenetics* | 0.75 | 0.95 | |||
| t(9;22) present | 58 | 54 (41-67)% | 22 (12-34)%ǂ | ||
| t(9;22) absent | 33 | 58 (40-74)%ǂ | 23 (10-39)%ǂ | ||
| Time to achieve CR1* | 0.16 | 0.84 | |||
| <=8 weeks | 47 | 41 (28-56)% | 27 (15-41)%ǂ | ||
| >8 weeks | 51 | 60 (46-73)%ǂ | 22 (12-34)%ǂ |
*
Data limited to nested cohort of 119 subjects (55 centers)
Abbrevations: HCT-CI: Hematopoietic Stem Cell Transplant-Comorbidity Index, CR: Complete Remission, TBI: Total Body Irradiation, Flu: Fludarabine, Bu: Busulfaran, CsA: Cyclosporine, MTX: Methotrexate, MMF: mycophenolate mofetil, MUD: matched unrelated donor, UCB: Umbilical Cord Blood, ATG: Anti-Thymocyte Globulin
&
mismatched (haplo=9)
ǂ
Less than 15 cases at risk at 3 years